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It Is All About Heart Rate.
Or Is It?*
Mohammad Sarraf, MD, Gary S. Francis, MD
Minneapolis, Minnesota
Although beta-blockers have been widely used to treat
various cardiovascular disorders since the introduction of
propranolol in the 1950s, the mechanism whereby clinical
benefit is derived is still not entirely clear. There has been a
fundamental question as to whether the quantitative con-
tribution to benefit is largely a product of a reduced heart
rate, or whether other established mechanisms of beta-
blockers may be driving much of the clinical benefit.
Contemporary data indicate that heart rate reduction is
responsible for about 60% of the improvement in left
ventricular function, whereas 30% is due to increased
contractility and a small amount is due to a reduction in
systemic vascular resistance (1). Among the non-heart
rate–lowering benefits of beta-blockers are their effects on
reduced force of contraction, antiarrhythmic properties,
inhibition of the renin-angiotensin-aldosterone system, an-
tiproliferative activity, and their ability to reduce systemic
vascular resistance. The mitigation of left ventricular re-
modeling associated with beta-blockers is likely in part due
to reduction in heart rate. Ivabradine, a pure bradycardic
agent, also has antiremodeling activity both in patients (2)
nd in animal models of heart failure (3).
See page 1938
It is well established that increased resting heart rate is a
risk factor for the development of cardiovascular events in
the general population (4), as it is in patients with known
cardiovascular disease (5,6). Moreover, there are now mul-
tiple analyses from various beta-blocker trials that indicate
an association between the reduction in heart rate and
favorable clinical outcomes (7–10). With the introduction of
ivabradine, we now have an agent that solely reduces heart
rate without altering other cardiac functions. Ivabradine is a
particularly fascinating molecule. In this issue of the Journal,
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board of Novartis.he authors (11) have used data from the SHIFT (Systolic
eart failure treatment with the If inhibitor ivabradine
rial) study and conclude that the heart rate–lowering
ffects of beta-blockers plus ivabradine are more important
n improving outcomes than the actual dose of beta-blocker.
he data verify that there is something very important about
owering heart rate in patients with heart failure (12). It now
ppears that the amount of reduction in heart rate is more
mportant than the specific dose of beta-blocker. This
nformation may be useful, since a substantial proportion of
atients with heart failure do not tolerate the doses of
eta-blockers used in the large clinical trials. It follows that
atients who are not tolerant to optimal beta-blocker doses
ay benefit from addition of ivabradine, although there are
o data to specifically support this concept. Perhaps “it is all
bout heart rate” after all. The lower the heart rate, the
etter the outcome.
Despite the observation by the SHIFT investigators that
eduction in heart rate is important for outcome, it is worth
ommenting on the possibility whereby this information
ould conceivably be misapplied. For example, suppose the
essage of the paper were misinterpreted to mean that as
ong as the heart rate is appropriately reduced, it makes little
ifference how it is reduced. In fact, one might reason that
vabradine could even be more widely applied to patients
ith heart failure who harbor relative contraindications to
eta-blockers, such as severe airway obstruction, frequent
ypoglycemic episodes, chronic fatigue, or simply the pa-
ient’s inability to tolerate even the smallest dose of the
eta-blocker. “Indication creep” is a well-known phenom-
non that occurs when a new drug or device is introduced to
linical practice. The indications for the new therapy tend to
xpand as a function of time and marketing rather than
o related scientific underpinnings. What if physicians
egan to use ivabradine in lieu of beta-blockers to reduce
eart rate? What if physicians completely abandoned the
se of beta-blockers in selected patients with heart failure in
avor of ivabradine, knowing that ivabradine may be better
olerated. Although there seems to be no question that
vabradine will reduce heart rate in this patient population,
he absence of beta-blocker therapy might result in serious
epercussions. For example, we have no information regard-
ng the use of ivabradine in prevention of sudden arrhythmic
eath, either in patients with heart failure or other cardio-
ascular disorders. This begs the question: is it really all
bout heart rate? Although lowering of the heart rate is
ritically important in patients with heart failure, as dem-
nstrated by these investigators, there are likely benefits of
eta-blockers that are beyond their ability to simply reduce
he heart rate. Perhaps the primary message for the clinician
rom the Swedberg et al. paper (11) is that adding ivabra-
ine to a beta-blocker in order to achieve heart rate
eduction is perhaps a better strategy than using small doses
f beta-blockers that fail to reduce the heart rate effectively.
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outcomes independent of reduction of heart rate? The
benefits of beta-blockers are related to alteration of many
downstream cellular and molecular pathways (13). Beta-
blockers to some extent reverse the fetal gene program
found in heart failure. In addition, beta-blockers alter gene
expression and facilitate the reversal of low ATPase-beta-
myosin heavy chain to high ATPase-beta-myosin heavy
chain (14). This results in more efficient contractile func-
tion. Beta-blockers likely reduce ventricular arrhythmias by
blocking beta-1 receptors throughout the myocardium,
whereas a drug like ivabradine has an isolated effect on
sinoatrial nodal tissue. It is therefore likely that beta-
blockers have more pronounced antiarrhythmic effects in
the failing heart than a drug such as ivabradine. Beta-
blockers have powerful antiremodeling properties. Ivabra-
dine also has antiremodeling properties (2,3). These obser-
vations suggest that reduction in heart rate may be a
common pathway to mitigate progressive remodeling, thus
emphasizing the need for clinicians to reduce heart rate
when treating their patients with heart failure.
How will ivabradine eventually fit in to the treatment of
heart failure? Because there are many patients who seem-
ingly are intolerant of maximal-dose beta-blockers, ivabra-
dine may be an ideal add-on drug to facilitate a further
reduction in heart rate. The authors have essentially demon-
strated that it is not the maximal dose of beta-blockers that is
most important. Rather, it is the magnitude of reduction in
heart rate when both drugs are on board that is most closely
associated with a favorable clinical outcome. If this strategy
proves to be safe and effective, the findings from the study have
the potential to change practice, which is the primary goal of
any clinical investigation. It seems unlikely that ivabradine
would be used as a stand-alone drug, but as the authors point
out, it is more likely to be used in addition to beta-blockers to
establish an adequate degree of bradycardia.
The authors are to be congratulated on advancing what
might be a potentially new therapeutic pathway. One
additional extrapolation from the data would be that if a
small dose of beta-blocker results in a substantial reduction
in heart rate, one could argue that continued titration of the
beta-blocker to the so-called “optimal dosing level” may not
be necessary. Another possibility is that patients who
tolerate the recommended dose of beta-blockers but persist
with little or no reduction in heart rate may benefit from a
higher dose of beta-blocker or the addition of ivabradine.
The age-old question of how beta-blockers favorably influ-
ence the course of heart failure remains incompletely an-
swered, but lowering heart rate seems to be very important.
The authors have brought us another step closer to embrac-
ing the concept that reduction in heart rate is a critical
element in the treatment of patients with heart failure. So,even though it is “all about heart rate,” we must continue to
recognize that beta-blockers and ivabradine are very differ-
ent drugs, sharing in common only the propensity to lower
heart rate. Under the best of circumstances, ivabradine may
be an interesting add-on therapy, but will likely be used
primarily in carefully selected patients.
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